Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$302000.0.

  • Anika Therapeutics' Exchange Rate Effect fell 18961.42% to -$302000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $21000.0, marking a year-over-year decrease of 8670.89%. This contributed to the annual value of -$48000.0 for FY2024, which is 16075.95% down from last year.
  • Per Anika Therapeutics' latest filing, its Exchange Rate Effect stood at -$302000.0 for Q3 2025, which was down 18961.42% from $345000.0 recorded in Q2 2025.
  • Anika Therapeutics' Exchange Rate Effect's 5-year high stood at $345000.0 during Q2 2025, with a 5-year trough of -$302000.0 in Q3 2025.
  • Moreover, its 5-year median value for Exchange Rate Effect was -$4000.0 (2022), whereas its average is $6368.4.
  • As far as peak fluctuations go, Anika Therapeutics' Exchange Rate Effect soared by 85000.0% in 2023, and later crashed by 92962.96% in 2024.
  • Over the past 5 years, Anika Therapeutics' Exchange Rate Effect (Quarter) stood at $118000.0 in 2021, then crashed by 158.47% to -$69000.0 in 2022, then soared by 210.14% to $76000.0 in 2023, then tumbled by 271.05% to -$130000.0 in 2024, then plummeted by 132.31% to -$302000.0 in 2025.
  • Its Exchange Rate Effect was -$302000.0 in Q3 2025, compared to $345000.0 in Q2 2025 and $108000.0 in Q1 2025.